Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: from Molecular Bases to Practical Considerations

Overview

Journal Autoimmune Dis

Publisher Wiley

Date 2014 Feb 15

PMID 24527207

Citations 9

Authors

Paolo Ripellino

Thomas Fleetwood

Roberto Cantello

Cristoforo Comi

Affiliations

Soon will be listed here.

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, in which both cellular and humoral immune responses are involved. The disease is clinically heterogeneous with some patients displaying pure motor form and others also showing a variable degree of sensory dysfunction; disease evolution may also differ from patient to patient, since monophasic, progressive, and relapsing forms are reported. Underlying such clinical variability there is probably a broad spectrum of molecular dysfunctions that are and will be the target of therapeutic strategies. In this review we first explore the biological bases of current treatments and subsequently we focus on the practical management that must also take into account pharmacoeconomic issues.

Citing Articles

Intravenous immunoglobulin preparations attenuate lysolecithin-induced peripheral demyelination in mice and comprise anti-large myelin protein zero antibody.

Setoguchi Y, Hayashi A, Kawada A, Ibusuki A, Yanaoka D, Saito R Proc Jpn Acad Ser B Phys Biol Sci. 2023; 99(2):48-60.

PMID: 36775342 PMC: 10020422. DOI: 10.2183/pjab.99.004.

Pediatric CIDP: Diagnosis and Management. A Single-Center Experience.

Lukawska M, Potulska-Chromik A, Lipowska M, Hoffman-Zacharska D, Olchowik B, Figlerowicz M Front Neurol. 2021; 12:667378.

PMID: 34276534 PMC: 8284159. DOI: 10.3389/fneur.2021.667378.

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.

Beydoun S, Sharma K, Bassam B, Pulley M, Shije J, Kafal A Front Neurol. 2021; 12:638816.

PMID: 33763019 PMC: 7982536. DOI: 10.3389/fneur.2021.638816.

Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.

Tichy E, Prosser B, Doyle D J Pharm Pract. 2020; 35(1):106-119.

PMID: 32677504 PMC: 8822190. DOI: 10.1177/0897190020938212.

Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).

Querol L, Crabtree M, Herepath M, Priedane E, Viejo Viejo I, Agush S J Neurol. 2020; 268(10):3706-3716.

PMID: 32583051 PMC: 8463372. DOI: 10.1007/s00415-020-09998-8.

References

Kiefer R, Kieseier B, Stoll G, Hartung H . The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol. 2001; 64(2):109-27. DOI: 10.1016/s0301-0082(00)00060-5. View

Merkies I, Schmitz P, van der Meche F, Samijn J, van Doorn P . Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002; 72(5):596-601. PMC: 1737884. DOI: 10.1136/jnnp.72.5.596. View

Leger J, Viala K, Nicolas G, Creange A, Vallat J, Pouget J . Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013; 80(24):2217-25. PMC: 3721095. DOI: 10.1212/WNL.0b013e318296e92b. View

van Doorn P, Brand A, Strengers P, Meulstee J, Vermeulen M . High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990; 40(2):209-12. DOI: 10.1212/wnl.40.2.209. View

Chio A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F . Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007; 78(12):1349-53. PMC: 2095630. DOI: 10.1136/jnnp.2007.114868. View

Dalakas M . Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002; 59(12 Suppl 6):S13-21. DOI: 10.1212/wnl.59.12_suppl_6.s13. View

Meyer Zu Horste G, Hartung H, Kieseier B . From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol. 2007; 3(4):198-211. DOI: 10.1038/ncpneuro0452. View

Merkies I, Schmitz P, van der Meche F, van Doorn P . Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve. 2003; 28(1):93-100. DOI: 10.1002/mus.10410. View

Mahdi-Rogers M, Swan A, van Doorn P, Hughes R . Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2010; (11):CD003280. DOI: 10.1002/14651858.CD003280.pub3. View

10.

Charmandari E, Chrousos G, Ichijo T, Bhattacharyya N, Vottero A, Souvatzoglou E . The human glucocorticoid receptor (hGR) beta isoform suppresses the transcriptional activity of hGRalpha by interfering with formation of active coactivator complexes. Mol Endocrinol. 2004; 19(1):52-64. DOI: 10.1210/me.2004-0112. View

11.

Zettl U, Gold R, Toyka K, Hartung H . Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol. 1995; 54(4):540-7. DOI: 10.1097/00005072-199507000-00008. View

12.

Gelfand E . Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012; 367(21):2015-25. DOI: 10.1056/NEJMra1009433. View

13.

Flammer J, Rogatsky I . Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol. 2011; 25(7):1075-86. PMC: 5417249. DOI: 10.1210/me.2011-0068. View

14.

Lehmann H, Hartung H, Hetzel G, Stuve O, Kieseier B . Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006; 63(8):1066-71. DOI: 10.1001/archneur.63.8.1066. View

15.

Brannagan 3rd T . Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst. 2011; 16 Suppl 1:3-13. DOI: 10.1111/j.1529-8027.2011.00298.x. View

16.

Eftimov F, Vermeulen M, van Doorn P, Brusse E, van Schaik I . Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012; 78(14):1079-84. DOI: 10.1212/WNL.0b013e31824e8f84. View

17.

Muley S, Kelkar P, Parry G . Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol. 2008; 65(11):1460-4. DOI: 10.1001/archneur.65.11.1460. View

18.

Vermeulen M . Intravenous immunoglobulin: a first-line treatment in CIDP?. Lancet Neurol. 2008; 7(2):115-6. DOI: 10.1016/S1474-4422(07)70330-7. View

19.

van Schaik I . First-line treatment for CIDP: a new piece of the puzzle. Lancet Neurol. 2012; 11(6):478-9. DOI: 10.1016/S1474-4422(12)70101-1. View

20.

Mendell J, Barohn R, Freimer M, Kissel J, King W, Nagaraja H . Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001; 56(4):445-9. DOI: 10.1212/wnl.56.4.445. View